JP2022500419A5 - - Google Patents
Info
- Publication number
- JP2022500419A5 JP2022500419A5 JP2021513959A JP2021513959A JP2022500419A5 JP 2022500419 A5 JP2022500419 A5 JP 2022500419A5 JP 2021513959 A JP2021513959 A JP 2021513959A JP 2021513959 A JP2021513959 A JP 2021513959A JP 2022500419 A5 JP2022500419 A5 JP 2022500419A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- cytotoxic
- receptor
- population
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024110682A JP2024149496A (ja) | 2018-09-13 | 2024-07-10 | 腫瘍を治療するためのナチュラルキラー細胞組成物および免疫療法の方法 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862730939P | 2018-09-13 | 2018-09-13 | |
| US62/730,939 | 2018-09-13 | ||
| US201962821360P | 2019-03-20 | 2019-03-20 | |
| US62/821,360 | 2019-03-20 | ||
| US201962841768P | 2019-05-01 | 2019-05-01 | |
| US62/841,768 | 2019-05-01 | ||
| US201962875893P | 2019-07-18 | 2019-07-18 | |
| US62/875,893 | 2019-07-18 | ||
| PCT/US2019/050679 WO2020056045A1 (en) | 2018-09-13 | 2019-09-11 | Natural killer cell compositions and immunotherapy methods for treating tumors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024110682A Division JP2024149496A (ja) | 2018-09-13 | 2024-07-10 | 腫瘍を治療するためのナチュラルキラー細胞組成物および免疫療法の方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022500419A JP2022500419A (ja) | 2022-01-04 |
| JP2022500419A5 true JP2022500419A5 (cg-RX-API-DMAC7.html) | 2022-09-20 |
| JP7520818B2 JP7520818B2 (ja) | 2024-07-23 |
Family
ID=69778429
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021513959A Active JP7520818B2 (ja) | 2018-09-13 | 2019-09-11 | 腫瘍を治療するためのナチュラルキラー細胞組成物および免疫療法の方法 |
| JP2024110682A Pending JP2024149496A (ja) | 2018-09-13 | 2024-07-10 | 腫瘍を治療するためのナチュラルキラー細胞組成物および免疫療法の方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024110682A Pending JP2024149496A (ja) | 2018-09-13 | 2024-07-10 | 腫瘍を治療するためのナチュラルキラー細胞組成物および免疫療法の方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20210338727A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3850004B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7520818B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN113166225A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019337603B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3112195A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3068417T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020056045A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3805371A1 (en) | 2014-05-15 | 2021-04-14 | National University of Singapore | Modified natural killer cells and uses thereof |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| CN117363636A (zh) | 2017-03-27 | 2024-01-09 | 新加坡国立大学 | 一种编码嵌合受体的多核苷酸 |
| JP7360174B2 (ja) | 2018-02-09 | 2023-10-12 | ナショナル ユニヴァーシティー オブ シンガポール | ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用 |
| US12441787B2 (en) | 2018-04-02 | 2025-10-14 | National University Of Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| WO2020044239A1 (en) | 2018-08-29 | 2020-03-05 | National University Of Singapore | A method to specifically stimulate survival and expansion of genetically-modified immune cells |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| CN114651003A (zh) | 2019-09-10 | 2022-06-21 | 黑曜石疗法公司 | 用于可调调节的ca2-il15融合蛋白 |
| CN111423517B (zh) * | 2020-04-15 | 2023-05-12 | 赛德特生物制药有限公司 | 一种肿瘤细胞干性限制型car及其应用 |
| MX2022015586A (es) | 2020-06-12 | 2023-03-15 | Nkarta Inc | Linfocitos citolíticos naturales modificados genéticamente para inmunoterapia de cáncer dirigida a cd70. |
| WO2022215843A1 (ko) * | 2021-04-06 | 2022-10-13 | (주)에스엠티바이오 | 암 환자에 대하여 자연살해세포를 이용한 면역 항암 치료의 치료 반응성을 예측하는 방법 |
| CA3218640A1 (en) * | 2021-05-13 | 2022-11-17 | Kanya Lakshmi RAJANGAM | Dosing regimens for cancer immunotherapy |
| KR20240051112A (ko) | 2021-07-01 | 2024-04-19 | 인답타 세라뷰틱스 인코포레이티드 | 조작된 자연 살해(nk) 세포 및 관련 방법 |
| CN118215683A (zh) * | 2021-11-09 | 2024-06-18 | 悟境股份有限公司 | 记忆nk细胞和抗癌双特异性分子的组合癌症疗法 |
| TW202405165A (zh) * | 2022-04-14 | 2024-02-01 | 日商第一三共股份有限公司 | 編碼膜型細胞激素及tnf受體超家族分子之細胞內域的多核苷酸 |
| US20250375524A1 (en) | 2022-06-30 | 2025-12-11 | Indapta Therapeutics, Inc. | Combination of engineered natural killer (nk) cells and antibody therapy and related methods |
| WO2024080726A1 (ko) * | 2022-10-13 | 2024-04-18 | (주) 테라베스트 | 자연살해세포 및 토포이소머라제 저해제를 유효성분으로 포함하는 암 예방 및 치료용 약학 조성물 |
| CN120092090A (zh) * | 2022-11-07 | 2025-06-03 | 上海先博生物科技有限公司 | 工程化嵌合抗原受体免疫细胞及其应用 |
| JP2025538424A (ja) * | 2022-11-16 | 2025-11-28 | ンカルタ・インコーポレイテッド | 併用療法の投与レジメン |
| WO2024254774A1 (zh) * | 2023-06-14 | 2024-12-19 | 香港北恒生物科技有限公司 | 免疫细胞联合疗法 |
| EP4735011A1 (en) * | 2023-06-27 | 2026-05-06 | Nkarta, Inc. | Dosing regimens for treatment of cancer |
| CN118440901B (zh) * | 2024-04-26 | 2025-03-07 | 康立泰生物医药(青岛)有限公司 | 转基因nk细胞及其构建方法和应用 |
| CN118406654B (zh) * | 2024-04-26 | 2025-03-21 | 中国海洋大学 | 经修饰的nk细胞及其构建方法和应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0123276D0 (en) * | 2001-09-27 | 2001-11-21 | Imp College Innovations Ltd | Uses of agents that bind immune-system components |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| WO2005076843A2 (en) * | 2004-02-06 | 2005-08-25 | Elan Pharmaceuticals, Inc. | Methods and compositions for treating tumors and metastatic disease |
| WO2014040143A1 (en) * | 2012-09-17 | 2014-03-20 | Gray Bruce N | Method of treating cancer |
| SG11201505858VA (en) * | 2013-01-28 | 2015-09-29 | St Jude Childrens Res Hospital | A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease |
| WO2014140884A2 (en) * | 2013-03-15 | 2014-09-18 | Novelogics Biotechnology, Inc. | Methods and devices for removal of immunosuppressive ligands |
| CN107074957B (zh) * | 2014-01-13 | 2021-05-07 | 希望之城公司 | 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法 |
| WO2015150097A1 (en) * | 2014-04-04 | 2015-10-08 | Iomet Pharma Ltd | Indole derivatives for use in medicine |
| US9801627B2 (en) * | 2014-09-26 | 2017-10-31 | Ethicon Llc | Fastener cartridge for creating a flexible staple line |
| EP3805371A1 (en) * | 2014-05-15 | 2021-04-14 | National University of Singapore | Modified natural killer cells and uses thereof |
| EP3712171A1 (en) * | 2014-08-19 | 2020-09-23 | Novartis AG | Treatment of cancer using a cd123 chimeric antigen receptor |
| US10577417B2 (en) * | 2014-09-17 | 2020-03-03 | Novartis Ag | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| EP3240908A2 (en) * | 2014-12-30 | 2017-11-08 | F. Hoffmann-La Roche AG | Methods and compositions for prognosis and treatment of cancers |
| US10471098B2 (en) * | 2015-04-15 | 2019-11-12 | Prospect Chartercare Rwmc, Llc | Hepatic arterial infusion of CAR-T cells |
| US12241053B2 (en) * | 2015-10-09 | 2025-03-04 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
| MX2018005618A (es) | 2015-11-05 | 2018-08-01 | Juno Therapeutics Inc | Receptores quimericos que contienen dominios inductores de traf y composiciones y metodos relacionados. |
| US10875919B2 (en) * | 2016-04-26 | 2020-12-29 | Alector Llc | Chimeric receptors and methods of use thereof |
| TW201825511A (zh) * | 2016-09-09 | 2018-07-16 | 美商艾斯合顧問有限公司 | 表現免疫檢查點調節子的溶瘤病毒 |
| EP3532091A2 (en) * | 2016-10-29 | 2019-09-04 | H. Hoffnabb-La Roche Ag | Anti-mic antibidies and methods of use |
| WO2018124766A2 (ko) * | 2016-12-28 | 2018-07-05 | 주식회사 녹십자랩셀 | 키메라 항원 수용체 및 이를 발현하는 자연 살해 세포 |
| CN110913954A (zh) * | 2017-03-03 | 2020-03-24 | 黑曜石疗法公司 | 免疫疗法的组合物和方法 |
| CN117363636A (zh) * | 2017-03-27 | 2024-01-09 | 新加坡国立大学 | 一种编码嵌合受体的多核苷酸 |
-
2019
- 2019-09-11 ES ES19859765T patent/ES3068417T3/es active Active
- 2019-09-11 JP JP2021513959A patent/JP7520818B2/ja active Active
- 2019-09-11 CN CN201980067523.9A patent/CN113166225A/zh active Pending
- 2019-09-11 CA CA3112195A patent/CA3112195A1/en active Pending
- 2019-09-11 US US17/274,022 patent/US20210338727A1/en not_active Abandoned
- 2019-09-11 AU AU2019337603A patent/AU2019337603B2/en active Active
- 2019-09-11 WO PCT/US2019/050679 patent/WO2020056045A1/en not_active Ceased
- 2019-09-11 EP EP19859765.0A patent/EP3850004B1/en active Active
-
2024
- 2024-07-10 JP JP2024110682A patent/JP2024149496A/ja active Pending
-
2025
- 2025-09-10 US US19/325,376 patent/US20260069530A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Alnefaie et al. | Chimeric antigen receptor T-cells: an overview of concepts, applications, limitations, and proposed solutions | |
| Hodgins et al. | Killers 2.0: NK cell therapies at the forefront of cancer control | |
| Dai et al. | Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma | |
| Al-Haideri et al. | CAR-T cell combination therapy: the next revolution in cancer treatment | |
| Harris et al. | Immuno-oncology combinations: raising the tail of the survival curve | |
| Dempke et al. | Second-and third-generation drugs for immuno-oncology treatment—the more the better? | |
| CN110475571B (zh) | 细胞免疫疗法前细胞毒性预调理的替代 | |
| TWI786044B (zh) | 藉由投予pd-1抑制劑治療皮膚癌之方法 | |
| JP6787792B2 (ja) | がんの処置のための併用治療 | |
| Huang et al. | Wnt/β-catenin inhibitor ICG-001 enhances the antitumor efficacy of radiotherapy by increasing radiation-induced DNA damage and improving tumor immune microenvironment in hepatocellular carcinoma | |
| US20240066040A1 (en) | Ep4 inhibitors and use thereof | |
| Duru et al. | A window of opportunity: targeting cancer endothelium to enhance immunotherapy | |
| Dolkar et al. | New developments in immunotherapy for SCLC | |
| KR20150080507A (ko) | 면역 반응의 향상 | |
| JP2022189827A (ja) | 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与 | |
| Huang et al. | Bispecific T cell engagers and their synergistic tumor immunotherapy with oncolytic viruses | |
| JP2021502416A5 (cg-RX-API-DMAC7.html) | ||
| Su et al. | Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond | |
| Morganti et al. | Combinations using checkpoint blockade to overcome resistance | |
| Demel et al. | Focus on monoclonal antibodies targeting B‐cell maturation antigen (BCMA) in multiple myeloma: update 2021 | |
| WO2022052874A1 (zh) | 西奥罗尼联合免疫检查点抑制剂在抗肿瘤治疗中的应用 | |
| Kim et al. | Calcipotriol, a synthetic Vitamin D analog, promotes antitumor immunity via CD4+ T-dependent CTL/NK cell activation | |
| Li et al. | Chimeric antigen receptor-immune cells against solid tumors: Structures, mechanisms, recent advances, and future developments | |
| JP2024513506A (ja) | がんの治療のためのCD47/SIRPα結合及びNEDD8活性化酵素E1調節サブユニットの共阻害 | |
| Swan et al. | The evolving status of immunotherapies in multiple myeloma: the future role of bispecific antibodies |